secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2024-02-06T23:59:59+00:00
Accession:  0001493152-24-005085
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.03, 3.02, 5.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

AgeX draws $500k note, converts preferred shares giving Juvenescence 75.6% control, extends Serina merger deadline
--------------------------------------------------------------------------------

- Drew $500,000 under secured convertible note with Juvenescence; repayment due Feb 14, 2024.
- Converted 211,600 Series A and 148,400 Series B preferred shares into 50M common shares for Juvenescence.
- Juvenescence now holds 66.4M shares (75.6% of outstanding); change in control of AgeX deemed to have occurred.
- Merger agreement with Serina extended to April 29, 2024; Juvenescence entered support agreement to vote in favor.
- Post-merger, Serina holders expected to own ~75% of combined company; AgeX holders ~25%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000149315224005085/0001493152-24-005085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000149315224005085/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-005085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer